Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas (2017)
myristoyl-TP-iRGE (scrambled control)
Sequence: CH3(CH)13GWTLNSAGYLLGKINLKALAALAKKILGGGGKCRGEKGPDC
| Experiment Id | EXP002411 |
|---|---|
| Paper | Tumor-Penetrating Delivery of siRNA against TNFα to Human Vestibular Schwannomas |
| Peptide | myristoyl-TP-iRGE (scrambled control) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10:1 peptide:siRNA molar ratio |
| Rna Concentration | ~100 nM siRNA (in vitro) |
| Mixing Ratio | 10:1 peptide:siRNA |
| Formulation Format | non-covalent peptide–siRNA nanoparticles |
| Formulation Components | myristoyl-TP-iRGE + siRNA |
| Size Nm | 80.00 |
| Zeta Mv | 25.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HEI-193 schwannoma cells; primary human vestibular schwannoma cultures |
| Animal Model | |
| Administration Route | cell culture incubation |
| Output Type | gene knockdown |
| Output Value | No significant TNFα silencing vs controls |
| Output Units | |
| Output Notes | Used as negative control; uptake reduced compared to iRGD system |
| Toxicity Notes | No significant cytotoxicity reported |
| Curation Notes |